Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

The open-label study was designed to evaluate Keytruda as a neoadjuvant treatment, followed by Keytruda in combination with ...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA ... to superstar status and the risks associated with its off-label use. In the age of AI, large data sets – like the ...

These labels may indicate contents of package such as Flammability or Fragile or they may indicate directions for handling. Shipping and handling labels alert shipping personal to all handling ...

Keytruda reduced death or disease recurrence by 24% compared to placebo in the study, and Merck said it would move swiftly ahead with applications to add the new indication to the drug's label.

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

An application program developed for sale to the general public. Packaged software is designed to appeal to a large audience of users, and although the programs may be tailored to a user's taste ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

In particular, Keytruda for cancer represents a key blockbuster ... costs related to product governance ESG risks (such as off-label marketing or litigation related to side effects), and model ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...